Request Trial
24 August 2018Asia-Pacific

Finnegan partner joins Quinn Emanuel in Tokyo

York Faulkner, an IP partner from Finnegan, Henderson, Farabow, Garrett & Dunner, has joined Quinn Emanuel Urquhart & Sullivan in Tokyo.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia-Pacific
Australia boutique hires experienced life sciences litigator
23 February 2023   New recruit joins from DLA Piper and will head up firm’s litigation team | Previously worked on Pfizer v Samsung Bioepis, Jusand v Rattlejack & Murray Engineering, and Pfizer v Sandoz | Follows prosecutor Chris Vindurampulle who joined in October last year.
Asia-Pacific
Australian court rejects Boehringer opposition bid against MSD unit’s anti-parasitic drug patent
24 May 2022   The Federal Court of Australia has refused an appeal request in a decade-long case brought by Boehringer Ingelheim Animal Health against MSD subsidiary, Intervet International.
Asia-Pacific
Wyeth secures Australian injunction against MSD vaccine
30 November 2020   The Federal Court of Australia has granted Pfizer subsidiary Wyeth’s bid for an injunction against Merck Sharp Dohme in a dispute over vaccine patents.


Editor's picks

SCOTUS shuts the door on Entresto ‘after-arising technology’ review
Americas
SCOTUS shuts the door on Entresto ‘after-arising technology’ review
17 December 2025

Editor's picks

Americas
SCOTUS shuts the door on Entresto ‘after-arising technology’ review
17 December 2025

More features

Mental health in IP: ‘We have a clear picture of the problem’
From Edwards to Insulet: Three key medical device cases of 2025
Edwards v Meril: Behind the UPC’s landmark medtech showdown
5 ways the USPTO director is changing US innovation
EU unveils sweeping pharma, biotech, and medical device reforms
Mirum targets generics in quartet of suits over liver treatment
Hogan Lovells and Cadwalader strike historic deal to create $3.6bn firm
Edwards v Meril: 3 insights from the UPC Court of Appeal’s decision